These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34716670)

  • 21. An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus.
    Hisada R; Atsumi T
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management.
    Radin M; Ugolini-Lopes MR; Sciascia S; Andrade D
    Semin Arthritis Rheum; 2018 Aug; 48(1):117-120. PubMed ID: 29395258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
    Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort.
    Zhao Y; Huang C; Qi W; Zhou Y; Zhao J; Wang Q; Tian X; Li M; Zhao Y; Zeng X
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL).
    Savelli SL; Roubey RAS; Kitzmiller KJ; Zhou D; Nagaraja HN; Mulvihill E; Barbar-Smiley F; Ardoin SP; Wu YL; Yu CY
    Front Immunol; 2019; 10():885. PubMed ID: 31134052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.
    Unlu O; Erkan D; Barbhaiya M; Andrade D; Nascimento I; Rosa R; Banzato A; Pengo V; Ugarte A; Gerosa M; Ji L; Efthymiou M; Branch DW; de Jesus GR; Tincani A; Belmont HM; Fortin PR; Petri M; Rodriguez E; Pons-Estel GJ; Knight JS; Atsumi T; Willis R; Zuily S; Tektonidou MG;
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):134-141. PubMed ID: 29669399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus.
    Mok MY; Chan EY; Fong DY; Leung KF; Wong WS; Lau CS
    J Rheumatol; 2005 Apr; 32(4):622-8. PubMed ID: 15801016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome.
    Udry S; Peréz SM; Belizna C; Aranda F; Esteve-Valverde E; Wingeyer SP; Fernández-Romero DS; Latino JO; de Larrañaga G; Alijotas-Reig J
    Lupus; 2022 Mar; 31(3):354-362. PubMed ID: 35157809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.
    Tebo AE; Willis R; Jaskowski TD; Guerra M; Pierangeli SS; Salmon J; Petri M; Branch DW
    Clin Chim Acta; 2016 Sep; 460():107-13. PubMed ID: 27346478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.
    Alpert D; Mandl LA; Erkan D; Yin W; Peerschke EI; Salmon JE
    Ann Rheum Dis; 2008 Mar; 67(3):395-401. PubMed ID: 17644539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
    Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
    Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up.
    Tarr T; Lakos G; Bhattoa HP; Soltesz P; Shoenfeld Y; Szegedi G; Kiss E
    Clin Rev Allergy Immunol; 2007 Apr; 32(2):131-7. PubMed ID: 17916982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers.
    Sloan E; Wright T; Zuo Y
    Lupus; 2021 Apr; 30(5):828-832. PubMed ID: 33736541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent antiphospholipid-related deep vein thrombosis as presenting manifestation of systemic lupus erythematosus.
    Gattorno M; Molinari AC; Buoncompagni A; Acquila M; Amato S; Picco P
    Eur J Pediatr; 2000 Mar; 159(3):211-4. PubMed ID: 10664237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular retinal findings in asymptomatic patients with antiphospholipid syndrome secondary to systemic lupus erythematosus.
    Neto EDS; Neto TSR; Signorelli F; Balbi GGM; Higashi AH; Monteiro MLR; Bonfá E; Andrade DCO; Zacharias LC
    Clin Rheumatol; 2023 Aug; 42(8):2105-2114. PubMed ID: 37126136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.